Aether Bio is a technology company.
Aether Bio has raised $49.0M across 1 funding round.
Aether Bio has raised $49.0M in total across 1 funding round.
Aether Bio has raised $49.0M in total across 1 funding round.
Aether Bio's investors include Ascension Ventures, GE Ventures, Highland Capital Partners, Northpond Ventures, Social Capital, Tiger Global Management, Unless.
Aether Bio is a synthetic biology company developing AI-driven platforms to engineer novel enzymes and biocatalysts for sustainable manufacturing of complex compounds.[1][3][4] Its Molecular Assembler platform combines generative AI, machine learning, and proprietary high-throughput robotics to repurpose enzymes, enabling cheaper, greener production of materials for healthcare, advanced manufacturing, electronics, automotive, pharmaceuticals, plastics recycling, carbon capture, and chemical breakdown.[1][2][3] Serving industrial clients needing custom biocatalysts, Aether solves the challenge of inefficient chemical synthesis by mapping vast "sequence space" through massively parallel experiments, generating datasets far larger than competitors.[1][3][4] With 51-100 employees, $49.41M in funding, and $4M estimated revenue, the Menlo Park-based firm (founded 2017) is in a mature stage and actively onboarding select clients.[1][3]
Aether Bio was founded in 2017 by CEO Pavle Jeremic, whose vision stems from personal experience growing up in the US and war-torn ex-Yugoslavia, recognizing material scarcity as a root cause of conflict and violence.[5] Jeremic assembled a team of hardware engineers, coders, ML experts, and biologists to tackle enzyme engineering via AI and robotics, emerging from the need to efficiently discover biocatalysts amid millions of possibilities.[3][5] Early traction came from building proprietary hardware for unprecedented experimental scale, backed by investors like Good AI, Artis Ventures, Dolby Family Ventures, and Jeff Dean (Google AI), fueling evolution toward a platform dominating biological manufacturing data (95% globally in three years).[1][3][5]
Aether Bio rides the AI-synthetic biology convergence, accelerating enzyme engineering to enable a "new industrial revolution" in sustainable manufacturing amid global demands for greener chemicals, critical minerals, and circular economies.[3][5] Timing aligns with post-ChatGPT AI advances in protein design (akin to mapping language or the internet), combined with robotics scaling data generation, as commercial tools lag in throughput.[3][4] Favorable market forces include regulatory pushes for carbon capture, plastic recycling, and domestic competitiveness in biotech, positioning Aether to disrupt trillion-dollar chemical industries by making biocatalysis viable at scale.[1][3] It influences the ecosystem by owning dominant datasets, partnering with AI funds like Good AI, and enabling US leadership in bio-manufacturing against scarcity-driven challenges.[5]
Aether Bio is poised to expand its platform commercially, leveraging its data moat and hardware edge to secure more enterprise clients in high-stakes sectors like pharma and materials, potentially scaling revenues beyond $4M amid rising AI-bio investments.[1][3] Trends like generative AI for proteins, automation in labs, and sustainability mandates will propel growth, with influence evolving toward post-scarcity manufacturing—echoing its mission to end material-driven conflicts through abundant, engineered enzymes.[5] As the first to fully index sequence space, Aether could redefine industrial chemistry, starting from its scrappy origins to biotech dominance.[3][4]
Aether Bio has raised $49.0M across 1 funding round. Most recently, it raised $49.0M Series A in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2023 | $49.0M Series A | Ascension Ventures, GE Ventures, Highland Capital Partners, Northpond Ventures, Social Capital, Tiger Global Management, Unless |